Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 54

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4
Chunk 54
---
 is an AI-driven company specializing in molecular farming for the food sector, committed to providing sustainable alternative sources to animal-based proteins, while utilizing our GeneRator AI technology. We hold an approximately 40% stake in Finally, with the remaining ownership divided among TKH and the founding team (being the Chief Executive Officer and Chief Technology Officer of Finally).
 
Business Model
 
We capitalize on the value of our AI tech-engines through two distinct business models:
 

  1.    Licensing: we grant time-limited licenses to third parties, our subsidiaries, or related entities, allowing them to leverage our
                                   tech-engines for product development within specified commercial domains.                            
----------------------------------------------------------------------------------------------------------------------------------------
 
Typically, the potential revenue stream from this business model would be:
 

•   License fee and R&amp;D reimbursement;
------------------------------------------

•   Dividends to Evogene as a shareholder; and
----------------------------------------------

•   Significant one-time payment upon an exit event (in case Evogene is a main shareholder).
--------------------------------------------------------------------------------------------

  2.       Collaborations: we engage in collaborative ventures with industry leaders, pooling resources to drive joint product development.   
        Typically, our partners take the lead in later-stage development and commercialization, leveraging our unique tech-engines to identify
                                         the product candidate and optimize it towards a commercial product.                                  
----------------------------------------------------------------------------------------------------------------------------------------------
 
Typically, the potential revenue stream from this business model would be:
 

•   Upfront payments;
---------------------

•   R&amp;D fees; and
---------------------

•   Royalties from sales of end-products.
-----------------------------------------
 
As of the date of this Annual Report, Evogene commercializes MicroBoost AI, through two licensing agreements, the first with our subsidiary, Lavie Bio, for the development of ag-biological, and the second with our subsidiary, Biomica, for the development of drug based on human microbiome. In addition, Evogene commercializes MicroBoost AI, through collaboration with Verb Biotics LLC, to develop probiotics products.
 
With respect to ChemPass AI, Evogene commercializes it through a license agreement with our subsidiary, AgPlenus, for the development of ag-chemical products.
 
With respect to Generator AI, during 2024 Evogene commercialized it through the following license agreements: the first with our subsidiary, Canonic, for the development of medical cannabis products. Canonic ceased its operation during the first half of 2024. The second, with our subsidiary, Casterra, for the development of cast